Q-omics provides the consensus-scored MTFR1L profile across patient tissues and cancer cell-line models. MTFR1L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MTFR1L is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MTFR1L protein abundance shows 25,344 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, KIRC, and LUAD as cancer lineages where MTFR1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTFR1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTFR1L survival associations across molecular data types. MTFR1L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTFR1L RNA expression–survival associations across cancer types. High MTFR1L expression shows unfavorable associations in LGG, ACC and READ, but favorable associations in KIRP, KIRC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MTFR1L RNA expression.
This table summarizes MTFR1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTFR1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTFR1L shows lower tumor expression in KIRC, THCA, KIRP, BLCA, UCEC and KICH. The KIRC box plot shows higher MTFR1L RNA expression in normal versus tumor tissue (log2 FC = −0.744, t-test p < 0.001).
This table shows molecular features associated with MTFR1L in patient tissues and cancer cell lines. In patient samples, MTFR1L shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MTFR1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
